HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The importance of absolute bone mineral density in the assessment of antiresorptive agents used for the prevention of osteoporotic fractures.

Abstract
The usefulness of bone mineral density (BMD) monitoring during antiresorptive treatment is still controversial. This study aimed to determine which factors of change (absolute value or the percent change from the baseline) in BMD are associated with the risk of future fractures. A total of 565 postmenopausal osteoporosis who were treated antiresorptive drugs were included in this prospective observational study. Lumbar BMD (LBMD) was measured at baseline and 1-yr after the initial and subsequent incident fracture was observed. The percent changes in LBMD at 1 yr were 5.4 ± 6.4% and 118 (20.9%) achieved increased LBMD with change of classification to >-2.5 standard deviation (SD). After the initial 1-yr examination, incident fractures developed in 152 (26.9%). The incident fracture risk was significantly associated with the absolute value in LBMD, but not with the percent change. A Cox proportional hazard model demonstrated that increased LBMD with change of classification to >-2.5 SD was a significant predictor for a reduction in incident fractures (hazard ratio: 0.41, 95% confidence interval: 0.21-0.71). In conclusion, these results suggest that monitoring of the antifracture efficacy of antiresorptive treatments should be based on the absolute value of BMD. In particular, increased change to >-2.5 SD is important for reducing the future fracture risk.
AuthorsTatsuhiko Kuroda, Masataka Shiraki, Yumiko Shiraki, Shiro Tanaka
JournalJournal of clinical densitometry : the official journal of the International Society for Clinical Densitometry (J Clin Densitom) 2012 Oct-Dec Vol. 15 Issue 4 Pg. 392-398 ISSN: 1094-6950 [Print] United States
PMID22521539 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2012 The International Society for Clinical Densitometry. Published by Elsevier Inc. All rights reserved.
Chemical References
  • Bone Density Conservation Agents
Topics
  • Aged
  • Bone Density
  • Bone Density Conservation Agents (therapeutic use)
  • Female
  • Follow-Up Studies
  • Humans
  • Incidence
  • Japan (epidemiology)
  • Lumbar Vertebrae (injuries)
  • Middle Aged
  • Osteoporosis, Postmenopausal (complications, drug therapy, epidemiology)
  • Osteoporotic Fractures (epidemiology, etiology, prevention & control)
  • Proportional Hazards Models
  • Prospective Studies
  • Risk Factors
  • Spinal Fractures (epidemiology, etiology, prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: